IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea

Potential new treatment option for multiple myeloma patients in Korea. Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"),...

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today...

Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London

Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London

PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of...

DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies

DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies

SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell...

Guo Guangchang's Letter to Shareholders: Fosun International Pursues Progress through "Strategic Advancements and Exits"

Guo Guangchang's Letter to Shareholders: Fosun International Pursues Progress through "Strategic Advancements and Exits"

HONG KONG, March 31, 2025 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to its shareholders on 30 March, outlining the Company's strategic direction, accomplishments, and future plans. Dear...

Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development

Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development

CRANBURY, N.J., March 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka...

Fosun International Awarded TVB's Highest Honor "Outstanding ESG Award"

Fosun International Awarded TVB's Highest Honor "Outstanding ESG Award"

HONG KONG, Dec. 18, 2024 /PRNewswire/ -- On 13 December 2024, the "TVB ESG Awards" ceremony, hosted by Television Broadcasts Limited (hereinafter referred to as "TVB"), was held at the Hong Kong Convention and Exhibition Centre. Fosun International...

The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural...

menu
menu